nature research

Corresponding author(s):	Chai Hong Rim
Last updated by author(s):	2020/10/14

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
C	۱-	+i	c+	ics
_	1 4		\sim 1	и <

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed				
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A description of all covariates tested				
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and code				
Policy information about <u>availability of computer code</u>				
Data collection no software was used				
Data analysis no software was used				
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.				

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The authors declare that [the/all other] data supporting the findings of this study are available within the paper [and its supplementary information files]

Field spe	ocific roporting	
· ·	ecific reporting	
		ur research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	Behavioural & socia	
For a reference copy of t	the document with all sections, see <u>nature.</u>	com/documents/nr-reporting-summary-flat.pdf
Life scier	nces study desig	gn
All studies must dis	close on these points even when	the disclosure is negative.
Sample size	meta-analysis including 4762 patien	ts
Data exclusions	N/A	
Replication	N/A	
Randomization	N/A	
Blinding	N/A	
We require information	on from authors about some types of	aterials, systems and methods materials, experimental systems and methods used in many studies. Here, indicate whether each material, enot sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & exp	perimental systems	Methods
n/a Involved in th	·	n/a Involved in the study
Antibodies		ChIP-seq
Eukaryotic	cell lines	Flow cytometry
Palaeontol	ogy and archaeology	MRI-based neuroimaging
	d other organisms	
	earch participants	
Clinical dat		
Dual use re	esearch of concern	
Clinical data		
Policy information	about <u>clinical studies</u>	
All manuscripts should	d comply with the ICMJE guidelines fo	r <u>publication of clinical research</u> and a completed <u>CONSORT checklist</u> must be included with all submissions.
Clinical trial regis	tration N/A	

Study protocol

Online registration of the protocol was not performed.

Data collection

The Pubmed, MEDLINE, EMBASE, and Cochrane library were systematically searched by two independent reviewers for articles published up to March 4, 2020.

Outcomes

The primary endpoints were overall survival (OS) and progression-free survival (PFS). Grade ≥3 complications related to LCTs were assessed subjectively. Data were extracted using a pre-standardized form; PFS and OS data were estimated from descriptive graphs in the absence of numerical reports. Data recruitment was performed by two independent researchers and any disagreement was resolved by mutual discussion.